© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Psyence Biomedical Ltd. (PBM) stock surged +103.82%, trading at $5.87 on NASDAQ, up from the previous close of $2.88. The stock opened at $2.81, fluctuating between $2.73 and $9.97 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 14, 2026 | 2.63 | 2.95 | 2.63 | 2.95 | 37.3K |
| Apr 13, 2026 | 2.56 | 2.83 | 2.55 | 2.79 | 20.31K |
| Apr 10, 2026 | 2.55 | 2.75 | 2.48 | 2.67 | 52.88K |
| Apr 09, 2026 | 2.48 | 2.57 | 2.41 | 2.50 | 24.5K |
| Apr 08, 2026 | 2.65 | 2.65 | 2.40 | 2.49 | 20.86K |
| Apr 07, 2026 | 2.47 | 2.52 | 2.45 | 2.50 | 23.77K |
| Apr 06, 2026 | 2.55 | 2.56 | 2.50 | 2.53 | 7.23K |
| Apr 02, 2026 | 2.39 | 2.51 | 2.26 | 2.47 | 27.88K |
| Apr 01, 2026 | 2.42 | 2.43 | 2.33 | 2.37 | 11.96K |
| Mar 31, 2026 | 2.48 | 2.49 | 2.41 | 2.46 | 3.93K |
| Mar 30, 2026 | 2.53 | 2.60 | 2.34 | 2.52 | 31.83K |
| Mar 27, 2026 | 2.50 | 2.63 | 2.50 | 2.56 | 12.08K |
| Mar 25, 2026 | 2.42 | 2.43 | 2.36 | 2.43 | 5.44K |
| Mar 24, 2026 | 2.36 | 2.43 | 2.36 | 2.43 | 5.1K |
| Mar 23, 2026 | 2.38 | 2.49 | 2.38 | 2.43 | 15.49K |
| Mar 20, 2026 | 2.40 | 2.46 | 2.30 | 2.40 | 5.16K |
| Mar 19, 2026 | 2.59 | 2.59 | 2.28 | 2.35 | 18.83K |
| Mar 18, 2026 | 2.60 | 2.60 | 2.52 | 2.54 | 9.7K |
| Mar 17, 2026 | 2.50 | 2.59 | 2.40 | 2.59 | 14.54K |
| Mar 16, 2026 | 2.41 | 2.57 | 2.40 | 2.50 | 21.82K |
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
| Employees | 12 |
| Beta | 0.36 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |